CYP19A1 and endometrioid adenocarcinoma: Although aromatase inhibitors have become the gold standard for endocrine treatments in the postmenopausal patients with estrogen-dependent breast carcinoma, the therapeutic value of aromatase-inhibitors in estrogen-sensitive endometrioid carcinoma is also not clear [49].